This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
Study Type
EXPANDED_ACCESS
TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
Wake Forest
Winston-Salem, North Carolina, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.